Pharmaceuticals, Biotechnology & Life Sciences

Virbac’s Q1 2026 revenue up 7.7% as Supercharge4 drives double‑digit growth in the booming global dewormer market.

Satellos Bioscience, a TSX biotech pioneer, is redefining muscle‑regeneration therapy, targeting severe disorders with cutting‑edge science to transform patient care.

Allogene Therapeutics boosts investor confidence with a Nature Communications breakthrough on ALLO‑329 and a $175 million capital raise, positioning its dual‑target CAR‑T platform as a next‑generation cancer therapy.

Zhejiang Conba Pharmaceutical benefits from China’s new “price protection period” policy, boosting pricing stability for TCM products and fueling bullish market momentum.

Discover Zhejiang Anglikang Pharmaceutical’s market strength, 52‑week high, and robust R&D focus in APIs and critical‑care drugs.

Discover how Zymeworks Inc. is advancing cancer treatment with multifunctional biotherapeutics—boosting investor confidence, driving innovation, and shaping precision medicine.

Oncolytics Biotech Inc. tackles hard‑to‑treat cancers with its reovirus drug REOLYSIN while navigating stock volatility and financial hurdles—an investor’s look at its breakthrough potential.

Check out how Agenus Inc. defied expectations in Q1, breaking its 200‑day MA and showing a positive EPS amid a -1211.76 P/E—insider confidence, analyst split, and institutional interest suggest a possible biotech turnaround.

Merck KGaA’s strategy: harnessing 5.1%‑CAGR sphingolipid growth and $20.3 b downstream processing to boost pharma innovation, resilience, and shareholder value amid volatile German markets.

Humacyte, Inc. pioneers bioengineered tissue implants, advancing regenerative medicine despite financial challenges—explore its high‑risk, high‑reward biotech journey and investor outlook.